1. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study
by C. Madsen, M. R. Clausen, T. L. Plesner, A. Pasanen, T. Kuismanen, H. H. Bentzen, J. M. Jørgensen, I. B. Sillesen, B. M. Himmelstrup, D. Rønnov-Jessen, K. R. Jensen, A. M. Pettinger, M. Ludvigsen, S. Leppä, and F. A. d’Amore
BloodAdv
Volume 2(13):
July 10, 2018
© 2018 by The American Society of Hematology

2. C. Madsen et al. Blood Adv 2018;2:1562-1571
© 2018 by The American Society of Hematology

3. Consort diagram of training cohort.
C. Madsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Outcome by maintenance and type of induction treatment.
Outcome by maintenance and type of induction treatment. OS (A), PFS (B), and TFS (C) by maintenance and type of induction treatment (training cohort). Time calculated from initiation of first-line induction treatment.
C. Madsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Cumulative incidence of HT by maintenance and type of induction treatment (training cohort).
Cumulative incidence of HT by maintenance and type of induction treatment (training cohort). All patients (A), CHOP/CHOP-like (B), and CVP/CVP-like (C). Time calculated from initiation of first-line induction treatment.
C. Madsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

6. OS, PFS, and TFS by maintenance and type of induction treatment (validation cohort).
OS, PFS, and TFS by maintenance and type of induction treatment (validation cohort). OS (A), PFS (B), and TFS (C). Time calculated from initiation of first-line induction treatment.
C. Madsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology